[HTML][HTML] Treatment of Alzheimer's disease: beyond symptomatic therapies

FR Buccellato, M D'Anca, GM Tartaglia… - International Journal of …, 2023 - mdpi.com
In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of
dementia and one of the first chronic diseases in elderly people. With 55 million people …

[HTML][HTML] New treatment strategies for Alzheimer's disease: is there a hope?

I Aprahamian, F Stella, OV Forlenza - Indian Journal of Medical …, 2013 - journals.lww.com
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and
corresponds to the most common cause of dementia worldwide. Although not fully …

Therapeutics of Alzheimer's disease: Past, present and future

R Anand, KD Gill, AA Mahdi - Neuropharmacology, 2014 - Elsevier
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …

[HTML][HTML] Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update

LK Huang, YC Kuan, HW Lin, CJ Hu - Journal of Biomedical Science, 2023 - Springer
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …

Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer's disease

S Ghosh, S Durgvanshi, S Agarwal… - Current …, 2020 - ingentaconnect.com
Alzheimer's disease (AD) is a chronic neurodegenerative disease affecting the elderly. AD is
associated with a progressive decline in memory and cognitive abilities, drastic changes in …

[HTML][HTML] Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease

T Athar, K Al Balushi, SA Khan - Molecular biology reports, 2021 - Springer
Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex,
multifactorial, unalterable, and progressive in nature. The currently approved therapy …

[HTML][HTML] Two decades of new drug discovery and development for Alzheimer's disease

Z Liu, A Zhang, H Sun, Y Han, L Kong, X Wang - RSC advances, 2017 - pubs.rsc.org
Alzheimer's disease is a progressive and irreversible neurodegenerative disease,
associated with a decreased cognitive function and severe behavioral abnormalities. Due to …

[HTML][HTML] Symptomatic and disease-modifying therapy pipeline for Alzheimer's disease: Towards a personalized polypharmacology patient-centered approach

X Morató, V Pytel, S Jofresa, A Ruiz… - International Journal of …, 2022 - mdpi.com
Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions

A Abeysinghe, R Deshapriya, C Udawatte - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

Alzheimer's disease: a systemic review of substantial therapeutic targets and the leading multi-functional molecules

T Umar, N Hoda - Current Topics in Medicinal Chemistry, 2017 - ingentaconnect.com
Alzheimer's Disease (AD) is a fatal neurodegenerative disorder, having a complex aetiology
with numerous possible drug targets. There are targets that have been known for years …